October 7, 2024
AstraZeneca to license CSPC Pharmaceutical’s lipid-lowering therapy
AstraZeneca has signed an exclusive agreement to license CSPC Pharmaceutical’s new lipid-lowering therapy, YS2302018, for treating patients with dyslipidaemia.